Literature DB >> 20712456

Interleukin-28 and interleukin-29: novel regulators of skin biology.

Kerstin Wolk1, Katrin Witte, Robert Sabat.   

Abstract

The skin forms an essential barrier between the inside of an organism and the environment. In addition to its function in insulation, temperature regulation, and sensation, it protects the body against physical trauma, pathogens, UV radiation, and excessive water loss. Many processes necessary for maintaining the skin integrity, including antimicrobial/antiviral defense, wound healing, and removal of tumors, are regulated by cytokines. Accumulating results lead us to assume that interleukin (IL)-28 and IL-29, 2 novel members of the IL-10-interferon cytokine family, are important regulators of some of these processes. In the skin, IL-28 and IL-29 can be produced by virus-infected cells, maturing dendritic cells (DCs), and regulatory T-cells, and they mainly influence keratinocytes and melanocytes. In keratinocytes, IL-28 and IL-29 induce growth inhibition. Simultaneously, these cytokines increase the cellular synthesis of proteins that directly hinder virus replication and enhance the readiness to present viral antigens to immune cells. Further, IL-28 and IL-29 upregulate expression of viral and microbial sensing cellular receptors, including toll-like receptor (TLR)3, TLR2, and melanoma differentiation associated gene 5, and strengthen the cellular response to these receptors' ligands. Thereby, in the noninfected skin IL-28 and IL-29 enhance the capacity of keratinocytes to react to viral and microbial products and at least indirectly upregulate their inflammatory potential and innate immunity. IL-28 and IL-29 can act synergistically with other mediators secreted during DC maturation (eg, IL-20). In summary, IL-28/IL-29 may play an important role in the skin in the clearance of viral and microbial infections and in the removal of tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20712456     DOI: 10.1089/jir.2010.0064

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  11 in total

1.  Interleukin-29: Just an extra string in the bow of Th17 cells or a target for therapeutic exploitation?

Authors:  Andrew Johnston
Journal:  J Mol Med (Berl)       Date:  2016-04       Impact factor: 4.599

2.  Host regulatory network response to infection with highly pathogenic H5N1 avian influenza virus.

Authors:  Chengjun Li; Armand Bankhead; Amie J Eisfeld; Yasuko Hatta; Sophia Jeng; Jean H Chang; Lauri D Aicher; Sean Proll; Amy L Ellis; G Lynn Law; Katrina M Waters; Gabriele Neumann; Michael G Katze; Shannon McWeeney; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2011-08-24       Impact factor: 5.103

3.  Cytokine gene expression in the skin and peripheral blood of atopic dermatitis patients and healthy individuals.

Authors:  Elena S Fedenko; Olga G Elisyutina; Tatyana M Filimonova; Margarita N Boldyreva; Olga V Burmenskaya; Olga Yu Rebrova; Alexander A Yarilin; Rakhim M Khaitov
Journal:  Self Nonself       Date:  2011-04-01

Review 4.  Interferon-lambda: a new addition to an old family.

Authors:  Raymond P Donnelly; Sergei V Kotenko
Journal:  J Interferon Cytokine Res       Date:  2010-08       Impact factor: 2.607

5.  Interleukin-29 induces epithelial production of CXCR3A ligands and T-cell infiltration.

Authors:  Ellen Witte; Georgios Kokolakis; Katrin Witte; Katarzyna Warszawska; Markus Friedrich; Demetrios Christou; Stefan Kirsch; Wolfram Sterry; Hans-Dieter Volk; Robert Sabat; Kerstin Wolk
Journal:  J Mol Med (Berl)       Date:  2015-11-26       Impact factor: 4.599

Review 6.  Therapeutic opportunities of the IL-22-IL-22R1 system.

Authors:  Robert Sabat; Wenjun Ouyang; Kerstin Wolk
Journal:  Nat Rev Drug Discov       Date:  2014-01       Impact factor: 84.694

Review 7.  Interferon lambdas: the next cytokine storm.

Authors:  Christabel Kelly; Paul Klenerman; Eleanor Barnes
Journal:  Gut       Date:  2011-02-08       Impact factor: 23.059

8.  Activation of type III interferon genes by pathogenic bacteria in infected epithelial cells and mouse placenta.

Authors:  Hélène Bierne; Laetitia Travier; Tanel Mahlakõiv; Ludovic Tailleux; Agathe Subtil; Alice Lebreton; Anupam Paliwal; Brigitte Gicquel; Peter Staeheli; Marc Lecuit; Pascale Cossart
Journal:  PLoS One       Date:  2012-06-14       Impact factor: 3.240

Review 9.  T cell pathology in skin inflammation.

Authors:  Robert Sabat; Kerstin Wolk; Lucie Loyal; Wolf-Dietrich Döcke; Kamran Ghoreschi
Journal:  Semin Immunopathol       Date:  2019-04-26       Impact factor: 9.623

Review 10.  The role of IL-29 in immunity and cancer.

Authors:  Noah E Kelm; Ziwen Zhu; Vivi A Ding; Huaping Xiao; Mark R Wakefield; Qian Bai; Yujiang Fang
Journal:  Crit Rev Oncol Hematol       Date:  2016-08-10       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.